DEVELOPMENTAL FUNDS

发展基金

• 批准号: 8486665
• 负责人: MICHELLE M LE BEAU
• 金额: $ 29.19万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8486665
• 关键词: Area; Bioinformatics; Biostatistics Core; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Collaborations; Core Facility; Development; Doctor of Philosophy; Economics; Epidemiologic Studies; Epigenetic Process; Faculty; Funding; Genetic; Goals; Grant; Hematologic Neoplasms; Hematopoiesis; Human; Image; Immunotherapy; Informatics; Institution; Instruction; Investments; Lead; Leadership; Malignant Neoplasms; Medicine; Molecular; Patients; Peer Review; Pharmacogenomics; Pharmacology; Pilot Projects; Population; Population Research; Program Development; Publications; Research; Research Personnel; Services; Strategic Planning; Targeted Research; Therapeutic; Translational Research; cancer care; cancer prevention; economic outcome; interdisciplinary collaboration; leukemia/lymphoma; member; metabolomics; new technology; next generation sequencing; programs

PROJECT SUMMARY (See instructions): Over the past five years. Developmental Funds have been used to support Pilot Projects, recruitment of new Investigators, and development of new Core Facilities to further UCCCC strategic goals, including expansion of population and translational research, immunotherapy, and interdisciplinary and interprogrammatic collaborations. From 2008-2012, a CCSG Investment of $1,519,611 has yielded a remarkable return of $33,870,022 In peer-reviewed support, as well as publications and programmatic development. Support for 10 new investigators has contributed to enhancements in the Molecular Mechanisms of Cancer, Hematopoiesis and Hematological Malignancies, Pharmacogenomics and Experimental Therapeutics and Cancer Prevention and Control Programs. With one exception, all of these faculty have remained at the institution and are active members of the UCCCC. Examples of significant recruitments include: Tina Shih, PhD, a cancer economist who is leading the development of cancer economics in the CPC Program; Jianjun Chen, PhD, whose research in genetic and epigenetic alterations in leukemia and lymphoma strengthens the HHM Program, and Peter O'Donnell, MD, who is applying his expertise in pharmacogenomics and its application to lead the 1200 Patient Trial. Four new developing Core Facilities were supported with CCSG developmental funds: Epidemiology and Research Recruitment Core (ERRC), Human Imaging Research Office (HIRO), Metabolomics, and the Biofluids Unit, the latter now a full component of the Pharmacology Core Facility. In addition, unique bioinformatics services (next-generation sequencing informatics) were added to the Biostatistics Core Facility, and have now been integrated into the institutional Bioinformatics Core (a developing UCCCC core). The developing cores continue to grow and have significantly contributed to interdisciplinary collaborations and translational research. Over the next grant period, we are requesting $360,000/year for: 1) recruitment of new investigators ($120K); 2) Program development/Program Pilot Projects ($140K); and 3) development of new Core Facilities ($100K). These funds will be used to further the three components of our Strategic Plan: 1) the Personalized Cancer Care Consortium (PCCC); 2) the Center for Cancer Prevention and Population Medicine; and 3) the Program in Cancer Survivorship, Cancer Economics, and Outcomes. We will support the ERRC, HIRO, Bioinformatics, and Metabolomics developing cores in the initial years of the next CCSG cycle. It is anticipated that as the needs for other new technologies are identified, CCSG developmental funds will be applied to their development.

项目摘要（请参阅说明）： 在过去的五年中。发展基金已用于支持试点项目，新研究人员的招聘以及开发新的核心设施，以进一步发展UCCCC的战略目标，包括扩大人口和转化研究，免疫疗法，跨学科和跨学科合作。从2008年至2012年，CCSG的1,519,611美元的CCSG投资在同行评审的支持以及出版物和程序化开发中获得了33,870,022美元的显着回报。对10名新研究人员的支持有助于提高癌症，造血和血液恶性肿瘤，药物基因组学以及实验疗法以及预防癌症和控制计划的分子机制。除了一个例外，所有这些教师都保留在该机构中，并且是UCCCC的积极成员。重大招募的例子包括：蒂娜·西赫（Tina Shih），博士学位，一名癌症经济学家，正在领导CPC计划中癌症经济学的发展； Jianjun Chen博士，他在白血病和淋巴瘤的遗传和表观遗传改变方面的研究增强了HHM计划，以及医学博士Peter O'Donnell，他正在应用药物基因组学方面的专业知识及其应用于1200例患者试验。 CCSG的发展基金支持了四个新的开发核心设施：流行病学和研究招聘核心（ERRC），人类影像研究办公室（HIRO），代谢组学和生物流体单元，现在是药学核心设施的完整组成部分。此外，将独特的生物信息学服务（下一代测序信息学）添加到Biostatistics核心设施中，现在已将其集成到机构生物信息学核心（开发的UCCCC核心）中。发展中的核心继续增长，并为跨学科的合作和翻译研究做出了重大贡献。 在下一个赠款期间，我们要求以下$ 360,000的赠款：1）招募新调查人员（$ 120K）； 2）计划开发/计划试点项目（$ 140K）； 3）开发新的核心设施（$ 100K）。这些资金将用于进一步的战略计划的三个组成部分：1）个性化癌症护理联盟（PCCC）； 2）预防癌症和人口医学中心； 3）癌症生存，癌症经济学和结果的计划。我们将在下一个CCSG周期的最初几年中支持ERRC，HIRO，生物信息学和代谢组学开发核心。可以预料，由于确定了对其他新技术的需求，CCSG的发展基金将用于其开发。